Blood biomarkers in moderate-to-severe traumatic brain injury: Potential utility of a multi-marker approach in characterizing outcome

Frontiers in Neurology

Volumn 6, Issue MAY, 2015, Pages

  Di Battista, Alex P ^a,b,c   Buonora, John E ^d,e   Rhind, Shawn G ^b,f   Hutchison, Michael G ^f   Baker, Andrew J ^a,c,f   Rizoli, Sandro B ^a,c,f   Diaz Arrastia, Ramon ^d   Mueller, Gregory P ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^e BAYLOR UNIVERSITY   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

BDNF; GFAP; ICAM 5; MCP 1; NSE; PRDX 6; S100B

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM BINDING PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; NEURON SPECIFIC ENOLASE; PEROXIREDOXIN 6; PROTEIN S100B;

ADULT; AREA UNDER THE CURVE; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC APPROACH ROUTE; DISEASE SEVERITY; FEMALE; GLASGOW COMA SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; MORTALITY; NERVE REGENERATION; NERVOUS SYSTEM INFLAMMATION; PATHOGENESIS; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; TRAUMATIC BRAIN INJURY;

EID: 84930666179     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2015.00110     Document Type: Article

References (49)

1. McKee AC, Daneshvar DH. The neuropathology of traumatic brain injury. Handb Clin Neurol (2015) 127:45-66. doi:10.1016/B978-0-444-52892-6.00004-0.
2. Gaddam SSK, Buell T, Robertson CS. Systemic manifestations of traumatic brain injury. Handb Clin Neurol (2015) 127:205-18. doi:10.1016/B978-0-444-52892-6.00014-3.
3. Papa L, Robertson CS, Wang KKW, Brophy GM, Hannay HJ, Heaton S, et al. Biomarkers improve clinical outcome predictors of mortality following non-penetrating severe traumatic brain injury. Neurocrit Care (2015) 22:52-64. doi:10.1007/s12028-014-0028-2.
4. Mondello S, Hayes RL. Biomarkers. Handb Clin Neurol (2015) 127:245-65. doi:10.1016/B978-0-444-52892-6.00016-7.
5. Wang KKW, Moghieb A, Yang Z, Zhang Z. Systems biomarkers as acute diagnostics and chronic monitoring tools for traumatic brain injury. In: Proc. SPIE 8723, Sensing Technologies for Global Health, Military Medicine, and Environmental Monitoring III, Vol. 87230O (2013). doi:10.1117/12.2020030.
6. Di Battista AP, Rhind SG, Baker AJ. Application of blood-based biomarkers in human mild traumatic brain injury. Front Neurol (2013) 4:44. doi:10.3389/fneur.2013.00044.
7. Balu R. Inflammation and immune system activation after traumatic brain injury. Curr Neurol Neurosci Rep (2014) 14:484-484. doi:10.1007/s11910-014-0484-2.
8. Finnie JW. Pathology of traumatic brain injury. Vet Res Commun (2014) 38:297-305. doi:10.1007/s11259-014-9616-z.
9. Hinson HE, Rowell S, Schreiber M. Clinical evidence of inflammation driving secondary brain injury: a systematic review. J Trauma Acute Care Surg (2015) 78:184-91. doi:10.1097/TA.0000000000000468.
10. Denes A, Miyan JA. Brain-immune interactions in health and disease. Front Neurosci (2014) 8:382. doi:10.3389/fnins.2014.00382.
11. Wolf H, Frantal S, Pajenda G, Leitgeb J, Sarahrudi K, Hajdu S. Analysis of s100 calcium binding protein B serum levels in different types of traumatic intracranial lesions. J Neurotrauma (2015) 32:23-7. doi:10.1089/neu.2013.3202.
12. Lesko MM, O'Brien SJ, Childs C, Bouamra O, Rainey T, Lecky F. Comparison of several prognostic tools in traumatic brain injury including S100B. Brain Inj (2014) 28:987-94. doi:10.3109/02699052.2014.890743.
13. Egea-Guerrero JJ, Revuelto-Rey J, Murillo-Cabezas F, Muñoz-Sánchez MA, Vilches-Arenas A, Sánchez-Linares P, et al. Accuracy of the S100 βprotein as a marker of brain damage in traumatic brain injury. Brain Inj (2012) 26:76-82. doi:10.3109/02699052.2011.635360.
14. Ferreira LCB, Regner A, Miotto KDL, Moura SD, Ikuta N, Vargas AE, et al. Increased levels of interleukin-6,-8 and-10 are associated with fatal outcome following severe traumatic brain injury. Brain Inj (2014) 28:1311-6. doi:10.3109/02699052.2014.916818.
15. Chiaretti A, Genovese O, Aloe L, Antonelli A, Piastra M, Polidori G, et al. Interleukin 1β and interleukin 6 relationship with paediatric head trauma severity and outcome. Childs Nerv Syst (2005) 21:185-93. doi:10.1007/s00381-004-1032-1.
16. Savola O, Pyhtinen J, Leino TK, Siitonen S, Niemelä O, Hillbom M. Effects of head and extracranial injuries on serum protein S100B levels in trauma patients. J Trauma (2004) 56:1229-34 discussion 1234. doi:10.1097/01.TA.0000096644.08735.72.
17. Undén J, Bellner J, Eneroth M, Alling C, Ingebrigtsen T, Romner B. Raised serum S100B levels after acute bone fractures without cerebral injury. J Trauma (2005) 58:59-61. doi:10.1097/01.TA.0000130613.35877.75.
18. Yokobori S, Hosein K, Burks S, Sharma I, Gajavelli S, Bullock R. Biomarkers for the clinical differential diagnosis in traumatic brain injury-a systematic review. CNS Neurosci Ther (2013) 19(8):556-65. doi:10.1111/cns.12127.
19. Gradisek P, Osredkar J, Korsic M, Kremzar B. Multiple indicators model of long-term mortality in traumatic brain injury. Brain Inj (2012) 26:1472-81. doi:10.3109/02699052.2012.694567.
20. Diaz-Arrastia R, Wang KKW, Papa L, Sorani MD, Yue JK, Puccio AM, et al. Acute biomarkers of traumatic brain injury: relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein. J Neurotrauma (2014) 31:19-25. doi:10.1089/neu.2013.3040.
21. Buonora JE, Yarnell AM, Lazarus R. Multivariate analysis of traumatic brain injury: development of an assessment score. Front Neurol (2015) 6:68. doi:10.3389/fneur.2015.00068/abstract.
22. Olivecrona Z, Bobinski L, Koskinen L-OD. Association of ICP, CPP, CT findings and S-100B and NSE in severe traumatic head injury. Prognostic value of the biomarkers. Brain Inj (2015) 29:446-54. doi:10.3109/02699052.2014.989403.
23. Chabok SY, Moghadam AD, Saneei Z, Amlashi FG, Leili EK, Amiri ZM. Neuron-specific enolase and S100BB as outcome predictors in severe diffuse axonal injury. J Trauma Acute Care Surg (2012) 72:1654-7. doi:10.1097/TA.0b013e318246887e.
24. Meric E, Gunduz A, Turedi S, Cakir E, Yandi M. The prognostic value of neuron-specific enolase in head trauma patients. J Emerg Med (2010) 38:297-301. doi:10.1016/j.jemermed.2007.11.032.
25. Žurek J, Fedora M. The usefulness of S100B, NSE, GFAP, NF-H, secretagogin and Hsp70 as a predictive biomarker of outcome in children with traumatic brain injury. Acta Neurochir (Wien) (2012) 154:93-103. doi:10.1007/s00701-011-1175-2.
26. Vos PE, Lamers KJB, Hendriks JCM, van Haaren M, Beems T, Zimmerman C, et al. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology (2004) 62:1303-10. doi:10.1212/01.WNL.0000120550.00643.DC.
27. Bigler ED. Neuroinflammation and the dynamic lesion in traumatic brain injury. Brain (2013) 136:9-11. doi:10.1093/brain/aws342.
28. Jaerve A, Müller HW. Chemokines in CNS injury and repair. Cell Tissue Res (2012) 349:229-48. doi:10.1007/s00441-012-1427-3.
29. Semple BD, Bye N, Rancan M, Ziebell JM, Morganti-Kossmann MC. Role of CCL2 (MCP-1) in traumatic brain injury (TBI): evidence from severe TBI patients and CCL2-/-mice. J Cereb Blood Flow Metab (2010) 30:769-82. doi:10.1038/jcbfm.2009.262.
30. Finnie JW. Neuroinflammation: beneficial and detrimental effects after traumatic brain injury. Inflammopharmacology (2013) 21(4):309-20. doi:10.1007/s10787-012-0164-2.
31. Yang H. Structure, expression, and function of ICAM-5. Comp Funct Genomics (2012) 2012:368938. doi:10.1155/2012/368938.
32. Guo H, Tong N, Turner T, Epstein LG, McDermott MP, Kilgannon P, et al. Release of the neuronal glycoprotein ICAM-5 in serum after hypoxic-ischemic injury. Ann Neurol (2000) 48:590-602. doi:10.1002/1531-8249(200010)48:4<590:AID-ANA5>3.0.CO;2-7.
33. Rhodes JKJ, Sharkey J, Andrews PJD. The temporal expression, cellular localization, and inhibition of the chemokines MIP-2 and MCP-1 after traumatic brain injury in the rat. J Neurotrauma (2009) 26:507-25. doi:10.1089/neu.2008.0686.
34. Leonard EJ, Yoshimura T. Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today (1990) 11:97-101. doi:10.1016/0167-5699(90)90035-8.
35. Rhodes J, Sharkey J, Andrews P. Serum IL-8 and MCP-1 concentration do not identify patients with enlarging contusions after traumatic brain injury. J Trauma (2009) 66:1591-8. doi:10.1097/TA.0b013e31819a0344.
36. Corps KN, Roth TL, McGavern DB. Inflammation and neuroprotection in traumatic brain injury. JAMA Neurol (2015) 72(3):355-62. doi:10.1001/jamaneurol.2014.3558.
37. Kaplan GB, Vasterling JJ, Vedak PC. Brain-derived neurotrophic factor in traumatic brain injury, post-traumatic stress disorder, and their comorbid conditions: role in pathogenesis and treatment. Behav Pharmacol (2010) 21:427-37. doi:10.1097/FBP.0b013e32833d8bc9.
38. Poo MM. Neurotrophins as synaptic modulators. Nat Rev Neurosci (2001) 2:24-32. doi:10.1038/35049004.
39. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci (2001) 24:677-736. doi:10.1146/annurev.neuro.24.1.677.
40. Mahmood A, Goussev A, Kazmi H, Qu C, Lu D, Chopp M. Long-term benefits after treatment of traumatic brain injury with simvastatin in rats. Neurosurgery (2009) 65:187-91. doi:10.1227/01.NEU.0000343540.24780.D6 discussion 191-2, .
41. Siironen J, Juvela S, Kanarek K, Vilkki J, Hernesniemi J, Lappalainen J. The Met allele of the BDNF Val66Met polymorphism predicts poor outcome among survivors of aneurysmal subarachnoid hemorrhage. Stroke (2007) 38:2858-60. doi:10.1161/STROKEAHA.107.485441.
42. Krueger F, Pardini M, Huey ED, Raymont V, Solomon J, Lipsky RH, et al. The role of the Met66 brain-derived neurotrophic factor allele in the recovery of executive functioning after combat-related traumatic brain injury. J Neurosci (2011) 31:598-606. doi:10.1523/JNEUROSCI.1399-10.2011.
43. Manevich Y, Hutchens S, Halushka PV, Tew KD, Townsend DM, Jauch EC, et al. Peroxiredoxin VI oxidation in cerebrospinal fluid correlates with traumatic brain injury outcome. Free Radic Biol Med (2014) 72:210-21. doi:10.1016/j.freeradbiomed.2014.04.002.
44. Tulsawani R, Kelly LS, Fatma N, Chhunchha B, Kubo E, Kumar A, et al. Neuroprotective effect of peroxiredoxin 6 against hypoxia-induced retinal ganglion cell damage. BMC Neurosci (2010) 11:125. doi:10.1186/1471-2202-11-125.
45. DeFazio MV, Rammo RA, Robles JR, Bramlett HM, Dietrich WD, Bullock MR. The potential utility of blood-derived biochemical markers as indicators of early clinical trends following severe traumatic brain injury. World Neurosurg (2014) 81:151-8. doi:10.1016/j.wneu.2013.01.015.
46. Berger RPR, Dulani TT, Adelson PDP, Leventhal JMJ, Richichi RR, Kochanek PMP. Identification of inflicted traumatic brain injury in well-appearing infants using serum and cerebrospinal markers: a possible screening tool. Pediatrics (2006) 117:325-32. doi:10.1542/peds.2005-0711.
47. Leclerc E, Fritz G, Vetter SW, Heizmann CW. Binding of S100 proteins to RAGE: an update. Biochim Biophys Acta (2009) 1793:993-1007. doi:10.1016/j.bbamcr.2008.11.016.
48. Shanmugam N, Kim YS, Lanting L, Natarajan R. Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. J Biol Chem (2003) 278:34834-44. doi:10.1074/jbc.M302828200.
49. Lu J, Goh SJ, Tng PYL, Deng YY, Ling E-A, Moochhala S. Systemic inflammatory response following acute traumatic brain injury. Front Biosci (Landmark Ed) (2009) 14:3795-813. doi:10.2741/3489.